Selenium Treatment Effect in Auto-Immune Hashimoto Thyroiditis in Macedonian Population

Nevena Manevska, Sinisa Stojanoski, Tanja Makazlieva


Background: Selenium (Se), a necessary trace mineral for humans, has the highest concentration in the thyroid gland and is known of its anti-oxidant and anti-inflammatory properties. Many studies have reported that Se has a close relationship with auto-immune Hashimotos thyroiditis (HT), characterized by the presence of anti-thyroid peroxidase (aTPO) auto-antibodies.

Methods: Five hundred thyroid patients, males and females, mean age 46 19 years, with diagnosed HT, were included in the study. Euthyroid forms of HT were treated with Se only, while patients with thyroid-stimulating hormone (TSH) > 10 IU/mL were treated with both substitutional therapy of levothyroxine and Se.

Results: In around 37% of the patients treated with Se 3 50 g/day with aTPO > 1,000 IU/mL, aTPO remained unchanged after 12 months, while 24.16% had aTPO < 500 IU/mL and 38.20% had aTPO between 500 and 1,000 IU/mL. Eighty-three out of 150 (55.33%) patients treated with Se 2 50 g/day with aTPO between 500 and 1,000 IU/mL responded. More than half of the patients (91/172, 52.90%) with aTPO < 500 IU/mL treated with Se 50 g/day normalized in 1 year. In hypothyroid group of patients, 12 months after treatment with levothyroxine and Se, 47.18% were responders with aTPO > 1,000 IU/mL, while 79.20% with aTPO between 500 and 1,000 IU/mL. In euthyroid group (Se only), the biggest response (30.56%) was seen in patients with the highest titer of aTPO > 1,000 IU/mL.

Conclusion: Se treatment is effective in reducing the levels of aTPO in patients with HT, alone or in combination with levothyroxine. This is due to the anti-inflammatory and anti-oxidant effect of Se. Our study promotes the concept of Se treatment in patients with euthyroid or hypothyroid state, with increased titers of aTPO.

J Endocrinol Metab. 2019;9(1-2):22-28


Selenium; Hashimoto thyroiditis; Thyroid; aTPO

Full Text: HTML PDF

Browse  Journals  


Journal of Clinical Medicine Research

Journal of Endocrinology and Metabolism

Journal of Clinical Gynecology and Obstetrics


World Journal of Oncology

Gastroenterology Research

Journal of Hematology


Journal of Medical Cases

Journal of Current Surgery

Clinical Infection and Immunity


Cardiology Research

World Journal of Nephrology and Urology

Cellular and Molecular Medicine Research


Journal of Neurology Research

International Journal of Clinical Pediatrics



Journal of Endocrinology and Metabolism, bimonthly, ISSN 1923-2861 (print), 1923-287X (online), published by Elmer Press Inc.                     
The content of this site is intended for health care professionals.
This is an open-access journal distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License, which permits unrestricted
non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Creative Commons Attribution license (Attribution-NonCommercial 4.0 International CC-BY-NC 4.0)

This journal follows the International Committee of Medical Journal Editors (ICMJE) recommendations for manuscripts submitted to biomedical journals,
the Committee on Publication Ethics (COPE) guidelines, and the Principles of Transparency and Best Practice in Scholarly Publishing.

website:   editorial contact:
Address: 9225 Leslie Street, Suite 201, Richmond Hill, Ontario, L4B 3H6, Canada

© Elmer Press Inc. All Rights Reserved.

Disclaimer: The views and opinions expressed in the published articles are those of the authors and do not necessarily reflect the views or opinions of the editors and Elmer Press Inc. This website is provided for medical research and informational purposes only and does not constitute any medical advice or professional services. The information provided in this journal should not be used for diagnosis and treatment, those seeking medical advice should always consult with a licensed physician.